| ESC Council on hypertension position document on themanagement of hypertensive emergencies |
32 |
| Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology |
23 |
| PCSK9 and inflammation: a review of experimental and clinical evidence |
15 |
| Time to epinephrine and survival after paediatric out-of-hospital cardiac arrest |
13 |
| Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting |
12 |
| Interleukin-1 blockade for the treatment of pericarditis |
12 |
| Effect of oral beta-blocker treatment on mortality in contemporary post-myocardial infarction patients: a systematic review and meta-analysis |
11 |
| Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review |
10 |
| Neoatherosclerosis after drug-eluting stent implantation: a novel clinical and therapeutic challenge |
10 |
| Management and prognosis of atrial fibrillation in diabetic patients: an EORP-AF General Pilot Registry report |
10 |
| Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA(2)DS(2)-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke |
9 |
| A randomized, double-blind, placebo-controlled trial assessing the efficacy of S66913 in patients with paroxysmal atrial fibrillation |
7 |
| Adherence to dual antiplatelet therapy with ticagrelor in patients with acute coronary syndromes treated with percutaneous coronary intervention in real life. Results of the REAL-TICA registry |
7 |
| Platelet inhibition with standard vs. lower maintenance dose of ticagrelor early after myocardial infarction (ELECTRA): a randomized, open-label, active-controlled pharmacodynamic and pharmacokinetic study |
7 |
| Influence of intravenous fentanyl compared with morphine on ticagrelor absorption and platelet inhibition in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the PERSEUS randomized trial |
7 |
| Coronary artery disease severity and long-term cardiovascular risk in patients with myocardial infarction: a Danish nationwide register-based cohort study |
6 |
| Bleeding and ischaemic outcomes in patients treated with dual or triple antithrombotic therapy: systematic review and meta-analysis |
6 |
| Loop diuretics for chronic heart failure: a foe in disguise of a friend? |
6 |
| Trends in optimal medical therapy prescription and mortality after admission for acute coronary syndrome: a 9-year experience in a real-world setting |
6 |
| Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA(2)DS(2)-VASc score of 1 |
5 |
| Baseline low-density lipoprotein cholesterol to predict the extent of cardiovascular benefit from lipid-lowering therapies: a review |
5 |
| Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54 |
5 |
| Heart rate, beta-blocker use, and outcomes of heart failure with reduced ejection fraction |
4 |
| External applicability of the COMPASS trial: the Western Denmark Heart Registry |
4 |
| Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study |
4 |
| Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large healthcare system |
3 |
| Temporal trends in acutemyocardial infarction presentation and association with use of cardioprotective drugs: a nationwide registry-based study |
3 |
| Mortality and adverse events with brand and generic clopidogrel in the US Food and Drug Administration Adverse Event Reporting System |
3 |
| Clinical use of cangrelor: nationwide experience from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) |
3 |
| Trends in cardiovascular and bleeding outcomes in acute coronary syndrome patients treated with or without proton-pump inhibitors during the introduction of novel P2Y12 inhibitors: a five-year experience from a single-centre observational registry |
3 |
| Development of triglyceride-lowering drugs to address residual cardiovascular risk: strategic and clinical considerations |
3 |
| Safety and effectiveness of rivaroxaban and apixaban in patients with venous thromboembolism: a nationwide study |
3 |
| Early occurrence of drug intolerance as risk factor during follow-up in patients with acute coronary syndrome or coronary revascularization |
2 |
| Differences in the risk of stroke, bleeding events, and mortality between female and male patients with atrial fibrillation during warfarin therapy |
2 |
| Antithrombotic therapy after myocardial infarction in patients with atrial fibrillation undergoing percutaneous coronary intervention |
2 |
| Rationale and Design of the Effectiveness of LowEr maintenanCe dose of TicagRelor early After myocardial infarction (ELECTRA) pilot study |
2 |
| Circadian variation of ticagrelor-induced platelet inhibition in healthy adulty |
2 |
| New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk |
2 |
| Antithrombotic therapy use and clinical outcomes following thrombo-embolic events in patients with atrial fibrillation: insights from ARISTOTLE |
1 |
| Comparative effectiveness of enalapril, lisinopril, and ramipril in the treatment of patients with chronic heart failure: a propensity score-matched cohort study |
1 |
| Pre-admission use of platelet inhibitors and short-termstroke mortality: a population-based cohort study |
1 |
| Is P2Y(12) inhibitor therapy associated with an increased risk of cancer? |
1 |
| Adherence to dabigatran etexilate in atrial fibrillation patients intended to undergo electrical cardioversion |
1 |
| The quality of warfarin therapy and CHA(2)DS(2)-VASc score associate with the incidence of myocardial infarction and cardiovascular outcome in patients with atrial fibrillation: data from the nationwide FinWAF Registry |
1 |
| How to implement the recommendations of the 2018 ESC/ESH Hypertension Guidelines in a given patient: a step by step approach |
1 |
| High burden of drug therapy in adult congenital heart disease: polypharmacy as marker of morbidity and mortality |
0 |
| Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease: systematic review and meta-analysis |
0 |
